| Wesley Foster, | |
|
1900 Pine St, Abilene, TX 79601-2432 | |
| (325) 670-4220 | |
| (325) 670-4040 |
| Full Name | Wesley Foster |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 11 Years |
| Location | 1900 Pine St, Abilene, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700219631 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 632476 (Texas) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | AP119162 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center | Lubbock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lubbock Gastroenterology And Liver Associates Pllc | 0941630966 | 7 |
| Texas Tech University Health Sciences Center Lubbock | 4385549674 | 310 |
| Methodist Hospital Levelland | 8527041037 | 9 |
News Archive
The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
› Verified 2 days ago
| Entity Name | Lamb Healthcare Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700854288 PECOS PAC ID: 6103738471 Enrollment ID: O20040127000737 |
News Archive
The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
› Verified 2 days ago
| Entity Name | Methodist Hospital Levelland |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043328222 PECOS PAC ID: 8527041037 Enrollment ID: O20040607001572 |
News Archive
The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
› Verified 2 days ago
| Entity Name | Terry Memorial Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619991171 PECOS PAC ID: 0042281545 Enrollment ID: O20041129000247 |
News Archive
The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
› Verified 2 days ago
| Entity Name | Texas Tech University Health Sciences Center Lubbock |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063461358 PECOS PAC ID: 4385549674 Enrollment ID: O20110318000468 |
News Archive
The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
› Verified 2 days ago
| Entity Name | Lubbock Gastroenterology & Liver Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356979397 PECOS PAC ID: 0941630966 Enrollment ID: O20200415001281 |
News Archive
The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wesley Foster, Po Box 1198, Abilene, TX 79604-1198 Ph: (325) 670-4220 | Wesley Foster, 1900 Pine St, Abilene, TX 79601-2432 Ph: (325) 670-4220 |
News Archive
The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
› Verified 2 days ago
Erica Anne Piehl, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2277 | |
Miles C. Frazier, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-4220 Fax: 325-672-8292 | |
Mrs. Tina R. Gray, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2277 | |
Melanie Sarabia, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2277 | |
Kayaya Kabongo, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2277 | |
Margery A. Spivey, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2000 | |
Sean Patrick Mcfadden, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2000 |